Glycotope, founded in Berlin in 2000, is a clinical stage immuno-oncology company built on world-leading glycobiology experti ... se. A set of our highly innovative clinical and pre-clinical projects with focus on oncology/immuno-oncology are available for partnering. The Company has a mature and growing pipeline of proprietary cancer therapies. Our innovative GlycoExpress® technology enables the generation of high quality oncology and non-oncology candidates with fully human glycosylation improving activity, drug characteristics and side effect profiles. The GlycoBody platform generates highly specific mAbs against carbohydrate epitopes found only on tumor cells. In addition, our capabilities in early-stage research and development provide a wide range of services for biopharmaceutical companies incl. glycan analytics (N- and O-glycans) as well as a whole range of protein analytics, USP and DSP process development, assay development in immune oncology as well as clinical immunomonitoring (http://www.glycotope.com/biopharmaceuticals-services/). read more